FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952468349> ?p ?o ?g. }

• W2952468349 abstract "Routine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of surveillance was conducted between 2015 and 2017 to determine the therapeutic efficacy of artesunate–amodiaquine (AS–AQ) and artemether–lumefantrine (AL) in 10 sentinel sites across the country. The study was a one-arm, prospective, evaluation of the clinical, parasitological, and haematological responses to directly observed treatment with AS–AQ and AL among children 6 months to 9 years old with uncomplicated falciparum malaria. The WHO 2009 protocol on surveillance of anti-malaria drug efficacy was used for the study with primary outcomes as prevalence of day 3 parasitaemia and clinical and parasitological cure rates on day 28. Secondary outcomes assessed included patterns of fever and parasite clearance as well as changes in haemoglobin concentration. Day 3 parasitaemia was absent in all sites following treatment with AS–AQ whilst only one person (0.2%) was parasitaemic on day 3 following treatment with AL. Day 28 PCR-corrected cure rates following treatment with AS–AQ ranged between 96.7% (95% CI 88.5–99.6) and 100%, yielding a national rate of 99.2% (95% CI 97.7–99.7). Day 28 PCR-corrected cure rates following treatment with AL ranged between 91.3% (95% CI 79.2–97.6) and 100%, yielding a national rate of 96% (95% CI 93.5–97.6). Prevalence of fever declined by 88.4 and 80.4% after first day of treatment with AS–AQ and AL, respectively, whilst prevalence of parasitaemia on day 2 was 2.1% for AS–AQ and 1.5% for AL. Gametocytaemia was maintained at low levels (< 5%) during the 3 days of treatment. Post-treatment mean haemoglobin concentration was significantly higher than pre-treatment concentration following treatment with either AS–AQ or AL. The therapeutic efficacy of AS–AQ and AL is over 90% in sentinel sites across Ghana. The two anti-malarial drugs therefore remain efficacious in the treatment of uncomplicated malaria in the country and continue to achieve rapid fever and parasite clearance as well as low gametocyte carriage rates and improved post-treatment mean haemoglobin concentration." @default.
• W2952468349 created "2019-06-27" @default.
• W2952468349 creator A5004594547 @default.
• W2952468349 creator A5027098946 @default.
• W2952468349 creator A5037399687 @default.
• W2952468349 creator A5042303657 @default.
• W2952468349 creator A5044895496 @default.
• W2952468349 creator A5058019143 @default.
• W2952468349 creator A5064632585 @default.
• W2952468349 creator A5091309549 @default.
• W2952468349 creator A5091659739 @default.
• W2952468349 date "2019-06-24" @default.
• W2952468349 modified "2023-10-15" @default.
• W2952468349 title "Therapeutic efficacy of artesunate–amodiaquine and artemether–lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015–2017" @default.
• W2952468349 cites W1974204803 @default.
• W2952468349 cites W1977731028 @default.
• W2952468349 cites W1978736315 @default.
• W2952468349 cites W2006887406 @default.
• W2952468349 cites W2036678624 @default.
• W2952468349 cites W2083127706 @default.
• W2952468349 cites W2121843547 @default.
• W2952468349 cites W2143467023 @default.
• W2952468349 cites W2159307889 @default.
• W2952468349 cites W2232089863 @default.
• W2952468349 cites W2461365364 @default.
• W2952468349 cites W2512918063 @default.
• W2952468349 cites W2592130419 @default.
• W2952468349 cites W2594265828 @default.
• W2952468349 cites W2737472839 @default.
• W2952468349 cites W2802043998 @default.
• W2952468349 cites W2805309778 @default.
• W2952468349 cites W2826739133 @default.
• W2952468349 cites W2887472114 @default.
• W2952468349 cites W2895245324 @default.
• W2952468349 doi "https://doi.org/10.1186/s12936-019-2848-1" @default.
• W2952468349 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6591907" @default.
• W2952468349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31234874" @default.
• W2952468349 hasPublicationYear "2019" @default.
• W2952468349 type Work @default.
• W2952468349 sameAs 2952468349 @default.
• W2952468349 citedByCount "22" @default.
• W2952468349 countsByYear W29524683492019 @default.
• W2952468349 countsByYear W29524683492020 @default.
• W2952468349 countsByYear W29524683492021 @default.
• W2952468349 countsByYear W29524683492022 @default.
• W2952468349 countsByYear W29524683492023 @default.
• W2952468349 crossrefType "journal-article" @default.
• W2952468349 hasAuthorship W2952468349A5004594547 @default.
• W2952468349 hasAuthorship W2952468349A5027098946 @default.
• W2952468349 hasAuthorship W2952468349A5037399687 @default.
• W2952468349 hasAuthorship W2952468349A5042303657 @default.
• W2952468349 hasAuthorship W2952468349A5044895496 @default.
• W2952468349 hasAuthorship W2952468349A5058019143 @default.
• W2952468349 hasAuthorship W2952468349A5064632585 @default.
• W2952468349 hasAuthorship W2952468349A5091309549 @default.
• W2952468349 hasAuthorship W2952468349A5091659739 @default.
• W2952468349 hasBestOaLocation W29524683491 @default.
• W2952468349 hasConcept C126322002 @default.
• W2952468349 hasConcept C142724271 @default.
• W2952468349 hasConcept C185032368 @default.
• W2952468349 hasConcept C203014093 @default.
• W2952468349 hasConcept C2776120307 @default.
• W2952468349 hasConcept C2776992834 @default.
• W2952468349 hasConcept C2778048844 @default.
• W2952468349 hasConcept C2778059366 @default.
• W2952468349 hasConcept C2778118209 @default.
• W2952468349 hasConcept C2778371730 @default.
• W2952468349 hasConcept C2778629330 @default.
• W2952468349 hasConcept C2780780316 @default.
• W2952468349 hasConcept C71924100 @default.
• W2952468349 hasConceptScore W2952468349C126322002 @default.
• W2952468349 hasConceptScore W2952468349C142724271 @default.
• W2952468349 hasConceptScore W2952468349C185032368 @default.
• W2952468349 hasConceptScore W2952468349C203014093 @default.
• W2952468349 hasConceptScore W2952468349C2776120307 @default.
• W2952468349 hasConceptScore W2952468349C2776992834 @default.
• W2952468349 hasConceptScore W2952468349C2778048844 @default.
• W2952468349 hasConceptScore W2952468349C2778059366 @default.
• W2952468349 hasConceptScore W2952468349C2778118209 @default.
• W2952468349 hasConceptScore W2952468349C2778371730 @default.
• W2952468349 hasConceptScore W2952468349C2778629330 @default.
• W2952468349 hasConceptScore W2952468349C2780780316 @default.
• W2952468349 hasConceptScore W2952468349C71924100 @default.
• W2952468349 hasFunder F4320307851 @default.
• W2952468349 hasIssue "1" @default.
• W2952468349 hasLocation W29524683491 @default.
• W2952468349 hasLocation W29524683492 @default.
• W2952468349 hasLocation W29524683493 @default.
• W2952468349 hasLocation W29524683494 @default.
• W2952468349 hasOpenAccess W2952468349 @default.
• W2952468349 hasPrimaryLocation W29524683491 @default.
• W2952468349 hasRelatedWork W2006887406 @default.
• W2952468349 hasRelatedWork W2108896527 @default.
• W2952468349 hasRelatedWork W2125109931 @default.
• W2952468349 hasRelatedWork W2142960482 @default.
• W2952468349 hasRelatedWork W2163799012 @default.
• W2952468349 hasRelatedWork W2508762646 @default.
• W2952468349 hasRelatedWork W2807079642 @default.
• W2952468349 hasRelatedWork W2947473331 @default.
• W2952468349 hasRelatedWork W3004753694 @default.

• next